Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE-Reference-Cited by-同舟云学术

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE

Published:2024-05-09 Issue:7 Volume:65 Page:1070-1075
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Warfvinge Carl Fredrik,Gustafsson Johan,Roth Daniel,Tennvall Jan,Svensson Johanna,Bernhardt Peter,Åkesson Anna,Wieslander Elinore,Sundlöv Anna,Sjögreen Gleisner Katarina

Publisher

Society of Nuclear Medicine

Reference25 articles.

1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

2. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients;Sundlöv;Eur J Nucl Med Mol Imaging.,2022

3. Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment

4. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial;Del Prete;Eur J Nucl Med Mol Imaging.,2019

5. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05

2. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model;Journal of Medicinal Chemistry;2024-07-16